1. Advances and perspectives in applying deep learning for drug design and discovery / C. F. Lipinski [et al.] // Front. Robotics and AI. - 2019. - Vol. 6, N 108. https://doi.org/10.3389/frobt.2019.00108

2. Deep learning enables rapid identification of potent DDR1 kinase inhibitors / A. Zhavoronkov [et al.] // Nat. Biotechnol. - 2019. - Vol. 37, N 9. - P. 1038-1040. https://doi.org/10.1038/s41587-019-0224-x

3. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors / A. M. Andrianov [et al.] // J. Biomol. Struct. Dyn. - 2022. - Vol. 40, N 16. - P. 7555–7573. https://doi.org/10.1080/07391102.2021.1905559

4. Review on the use of Molecular Docking as the First Line Tool in Drug Discovery and Development / R. N. Sahoo [et al.] // Indian J. Pharm. Sci. - 2022. - Vol. 84, N 5. - P. 1334-1337. https://doi.org/10.36468/pharmaceutical-sciences.1031

5. Hollingsworth, S. A. Molecular dynamics simulation for all / S. A. Hollingsworth, R. O. Dror // Neuron. - 2018. - Vol. 99, N 6. - P. 1129–1143. https://doi.org/10.1016/j.neuron.2018.08.011

6. Разработка генеративной нейронной сети глубокого обучения для компьютерного дизайна потенциальных ингибиторов коронавируса SARS-CoV-2 / Н. А. Шульдов [и др.] // Математическая биология и биоинформатика. - 2022. - Т. 17, № 2. - С. 188–207. https://doi.org/10.17537/2022.17.188

7. Ullrich, S. The SARS-CoV-2 main protease as drug target / S. Ullrich, C. Nitsche // Bioorg. Med. Chem. Lett. - 2020. - Vol. 30, N 17. – Art. 127377. https://doi.org/10.1016/j.bmcl.2020.127377

8. Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) / S. G. Katre [et al.] // Futur. J. Pharm. Sci. - 2022. - Vol. 8, N 1. – Art. 36. https://doi.org/10.1186/s43094-022-00423-7

9. Exponential consensus ranking improves the outcome in docking and receptor ensemble docking / K. Palacio-Rodriguez [et al.] // Sci. Rep. – 2019. – Vol. 9, N 1. – Art. 5142. https://doi.org/10.1038/s41598-019-41594-3

10. Genheden, S. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities / S. Genheden, U. Ryde // Expert Opin. Drug Discov. - 2015. - Vol. 10, N 5. - P. 449-461. https://doi.org/10.1517/17460441.2015.1032936

11. Potent noncovalent inhibitors of the main Protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations / C. H. Zhang [et al.] // ACS Cent. Sci. - 2021. - Vol. 7, N 3. - P. 467–475. https://doi.org/10.1021/acscentsci.1c00039

12. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings / C. A. Lipinski [et al.] // Adv. Drug Deliv. Rev. - 1997. - Vol. 23, N 1–3. - P. 3–25. https://doi.org/10.1016/s0169-409x(96)00423-1

13. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants / M. T. Qamar [et al.] // J. Pharm. Anal. - 2020. - Vol. 10, N 4. - P. 313-319. https://doi.org/10.1016/j.jpha.2020.03.009

14. Sharma, G. Thermodynamic analysis reveals a temperature-dependent change in the catalytic mechanism of Bacillus stearothermophilus tyrosyl-tRNA synthetase / G. Sharma, E. A. First // J. Biol. Chem. - 2009. - Vol. 284, N 7. - P. 4179–4190. https://doi.org/10.1074/jbc.m808500200

15. Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions / C. Shen [et al.] // Brief. Bioinf. - 2021. - Vol. 22, N 1. - P. 497–514. https://doi.org/10.1093/bib/bbz173